HIV-1 Infection
Conditions
Keywords
HIV Infections, TMC114-TiDP29-C230, TMC114-C230, TMC114, HIV-1, Darunavir, Ritonavir, NRTI, Treatment Naive
Brief summary
The purpose of this study is to evaluate pharmacokinetics (what body does to medication), safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir (DRV/rtv) administered once daily, in combination with an investigator-selected background regimen consisting of other antiretrovirals (ARVs) ie, 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), in treatment-naive (never treated before) HIV-1 infected adolescents aged from 12 to \<18 years and weighing at least 40 kg.
Detailed description
This is an open-label (all people know the identity of the intervention), single-arm, Phase II study to evaluate the pharmacokinetics, safety, tolerability, and efficacy of darunavir/ritonavir (DRV/rtv) administered once daily, in combination an investigator-selected background regimen (2 NRTIs), in treatment-naive HIV-1 infected adolescents over 48 weeks. A total of 12 patients will be enrolled in this study. Patients will be considered treatment-naive if they have never received treatment with an ARV medication, including both investigational as well as commercially available ARVs indicated for the treatment of HIV-infection and ARVs for the treatment of hepatitis B infection with anti-HIV activity. The investigator-selected background regimen will consist of 2 NRTIs, either zidovudine/lamivudine or abacavir/lamivudine, whichever is approved and marketed or considered local standard of care for adolescents aged from 12 to \<18 years in a particular country. The study will consist of a 4-week screening period, a 48-week treatment period, and a 4-week follow-up period. Safety, efficacy, resistance (reduction in effectiveness of a medication), pharmacokinetic analyses, and pharmacodynamic (what medication does to body) analyses will be performed at Week 24 (primary analysis) and Week 48 (final analysis). Patients who will complete the 48 weeks of treatment with DRV/rtv and who will continue to benefit from this treatment, will have the opportunity to continue this treatment until they no longer benefit from the medication, until DRV is commercially available or can be accessed from another source (eg, access program, government program) or until the development program is discontinued.
Interventions
DRUGdarunavir
Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
DRUGritonavir
Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
DRUGzidovudine
NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
DRUGlamivudine
NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
DRUGabacavir
NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
Sponsors
Tibotec Pharmaceutical Limited
Tibotec Pharmaceuticals, Ireland
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a documented HIV-1 infection * Body weight from at least 40 kg at screening * Screening plasma HIV-1 RNA \>= 1000 copies/mL * Parents or legal representative and trial patients (where appropriate, depending on age and local regulation) willing and able to give consent and assent * General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial * Able to swallow darunavir tablets (400 mg) and ritonavir capsules (100 mg)
Exclusion criteria
* Patients with presence of any currently active conditions included in the listing of World Health Organisation (WHO) Clinical Stage 4 * Any condition (including, but not limited to, alcohol and drug use), which, in the opinion of the investigator, could compromise the patient's safety or adherence to the trial protocol * Previous or current use of antiretrovirals (ARVs) * Primary or acute HIV infection * Use of any investigational agents within 30 days prior to screening * Use of disallowed concomitant therapy * Pregnant or breast-feeding * Female patient of childbearing potential without use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period * Patients with clinical or laboratory evidence of significantly decreased hepatic function or decompensation (ie, liver insufficiency), irrespective of liver enzyme levels * Any active clinically significant disease (eg, cardiac dysfunction, pancreatitis, acute viral infection) or findings during screening of medical history or physical examination that are expected to compromise the patient's safety or outcome in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Virological Response[Viral Load <50 Copies/mL, TLOVR] | Week 24 | The analysis is based on virologic response defined as percentage of patients with confirmed plasma viral load \<50 HIV-1 RNA copies/mL at Week 24 calculated according to the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) algorithm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Virological Response [Viral Load <50 Copies/mL, FDA-SNAPSHOT] | Week 24 | The analysis is based on the last observed viral load (VL) data within the Week 24 window. Virologic response is defined as a VL\<50 copies/mL (observed case). Virologic Failure includes a) patients who had \>=50 copies/mL in the Week-24 window, b) patients who discontinued prior to Week 24 for lack or loss of efficacy, c) patients who had a switch in their background regimen that was not permitted by the protocol, and d) patients who discontinued for reasons other than adverse events (AEs)/death, and lack or loss of efficacy (provided their last available viral load was detectable). |
Countries
France, Ireland, Spain, Ukraine, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| DRV/Rtv Darunavir tablets 2 x 400 mg tablet once daily for 48 weeks. Ritonavir capsule 100 mg capsule once daily for 48 weeks. | 12 |
| Total | 12 |
Baseline characteristics
| Characteristic | DRV/Rtv |
|---|---|
| Age Continuous | 14.7 years STANDARD_DEVIATION 1.69 |
| Percentile for BMI | 47.5 BMI Percentile |
| Percentile for Height | 27.2 Height Percentile |
| Percentile for Weight | 51.6 Weight Percentile |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 11 / 12 |
| serious Total, serious adverse events | 3 / 12 |
Outcome results
Primary
Virological Response[Viral Load <50 Copies/mL, TLOVR]
The analysis is based on virologic response defined as percentage of patients with confirmed plasma viral load \<50 HIV-1 RNA copies/mL at Week 24 calculated according to the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) algorithm.
Time frame: Week 24
Population: The ITT analysis set was considered the primary efficacy analysis set.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| DRV/Rtv | Virological Response[Viral Load <50 Copies/mL, TLOVR] | Yes | 11 Participants |
| DRV/Rtv | Virological Response[Viral Load <50 Copies/mL, TLOVR] | No | 1 Participants |
Secondary
Virological Response [Viral Load <50 Copies/mL, FDA-SNAPSHOT]
The analysis is based on the last observed viral load (VL) data within the Week 24 window. Virologic response is defined as a VL\<50 copies/mL (observed case). Virologic Failure includes a) patients who had \>=50 copies/mL in the Week-24 window, b) patients who discontinued prior to Week 24 for lack or loss of efficacy, c) patients who had a switch in their background regimen that was not permitted by the protocol, and d) patients who discontinued for reasons other than adverse events (AEs)/death, and lack or loss of efficacy (provided their last available viral load was detectable).
Time frame: Week 24
Population: The ITT analysis set was considered the primary efficacy analysis set.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DRV/Rtv | Virological Response [Viral Load <50 Copies/mL, FDA-SNAPSHOT] | 12 Participants |